Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average – Time to Sell?

Shares of Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.74 and traded as low as $0.46. Vaxart shares last traded at $0.47, with a volume of 2,133,998 shares traded.

Vaxart Trading Down 7.3 %

The company has a market cap of $107.42 million, a P/E ratio of -1.15 and a beta of 0.82. The stock’s 50-day moving average price is $0.71 and its 200-day moving average price is $0.74.

Institutional Investors Weigh In On Vaxart

Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd raised its holdings in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 122,387 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Vaxart by 15.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its holdings in shares of Vaxart by 100.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 20,000 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Vaxart by 10.8% in the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 17,942 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 251,789 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.